COVID-19 is an additional factor in patients shying away from follow-up exams. Nuance Communication’s Sander Kloet shares his perspectives from SIIM on addressing this issue.
One of the most widespread impacts of the COVID-19 pandemic has been the delayed study. For many patients, their screening or diagnostic studies have been put on hold for the foreseeable future. But, the postponement is more than a simple delay – it is a compounding factor that is starting to make an already existing problem worse.
It is no secret in the industry that patients who fail to arrive for follow-up care are a pervasive pain point for practices. Add in the delay, the risk, and the fear associated with the pandemic, and it is recipe for an even deeper drop in imaging volume.
Related Content: Contacting Patients About Abnormal Findings Isn’t Enough to Prompt Follow-Up
To help practices address this issue – and potentially side-step it – Diagnostic Imaging spoke with Sander Kloet, senior director of product management, diagnostics, for Nuance Communications about his session during Society for Imaging Informatics in Medicine 2020 Virtual Meeting. Here, he shares his insights on the frequency of the problem during the pandemic, strategies facilities can use to reduce the impact of failed follow-ups, and proactive tactics practices can implement.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.